UA60599A - Способ метафилактики оксалатного уролитиаза - Google Patents
Способ метафилактики оксалатного уролитиаза Download PDFInfo
- Publication number
- UA60599A UA60599A UA2003010231A UA200310231A UA60599A UA 60599 A UA60599 A UA 60599A UA 2003010231 A UA2003010231 A UA 2003010231A UA 200310231 A UA200310231 A UA 200310231A UA 60599 A UA60599 A UA 60599A
- Authority
- UA
- Ukraine
- Prior art keywords
- oxalate
- metaphylaxis
- urolithiasis
- recurrent
- tocopherol
- Prior art date
Links
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 206010007027 Calculus urinary Diseases 0.000 title claims abstract description 14
- 208000008281 urolithiasis Diseases 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims abstract description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011709 vitamin E Substances 0.000 claims abstract description 5
- 229940046009 vitamin E Drugs 0.000 claims abstract description 5
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 239000004575 stone Substances 0.000 claims description 9
- 229960001295 tocopherol Drugs 0.000 claims description 9
- 239000011732 tocopherol Substances 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 3
- 238000012876 topography Methods 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 2
- 229940087168 alpha tocopherol Drugs 0.000 abstract 1
- 229960000984 tocofersolan Drugs 0.000 abstract 1
- 239000002076 α-tocopherol Substances 0.000 abstract 1
- 235000004835 α-tocopherol Nutrition 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 8
- 208000008852 Hyperoxaluria Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 206010029148 Nephrolithiasis Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 208000000913 Kidney Calculi Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000395 magnesium oxide Substances 0.000 description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NIFHFRBCEUSGEE-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O NIFHFRBCEUSGEE-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- MYLBTCQBKAKUTJ-UHFFFAOYSA-N 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine Chemical compound C1=CN=CC2=C(SC)C(C)=C(SC)N21 MYLBTCQBKAKUTJ-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009212 extracorporeal shock wave lithotripsy Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940096405 magnesium cation Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002036 metaphylactic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012273 nephrostomy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Способ метафилактики оксалатного уролитиаза включает в себя применение -токоферола (витамина Е).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2003010231A UA60599A (ru) | 2003-01-09 | 2003-01-09 | Способ метафилактики оксалатного уролитиаза |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2003010231A UA60599A (ru) | 2003-01-09 | 2003-01-09 | Способ метафилактики оксалатного уролитиаза |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA60599A true UA60599A (ru) | 2003-10-15 |
Family
ID=74240511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003010231A UA60599A (ru) | 2003-01-09 | 2003-01-09 | Способ метафилактики оксалатного уролитиаза |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA60599A (ru) |
-
2003
- 2003-01-09 UA UA2003010231A patent/UA60599A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shah et al. | Hyperoxaluria | |
| US20060240118A1 (en) | Pharmacologically active strong acid solutions | |
| Rasmussen et al. | The clinical effect of naproxen sodium after arthroscopy of the knee: a randomized, double-blind, prospective study | |
| Odoemene et al. | Ureterolithiasis: management in an environment with limited facilities | |
| JP2669818B2 (ja) | 胃腸障害の治療及び予防のためのニトロフラントインの使用 | |
| JP2007508371A (ja) | 軟骨再生剤としてアピゲニンを含有する骨関節炎治療組成物 | |
| EP3962471B1 (en) | Composition for the prevention and treatment of urinary stones | |
| UA60599A (ru) | Способ метафилактики оксалатного уролитиаза | |
| CN110799184A (zh) | 二甲双胍与丁酸钠于治疗慢性发炎造成的病状的用途 | |
| RU2496493C1 (ru) | Способ профилактики острого послеоперационного панкреатита | |
| Pillay et al. | Massive proteinuria associated with vesico-ureteral reflux | |
| US20100029590A1 (en) | Methods for treating or preventing hemorrhagic cystitis using a glycerophosphate salt | |
| UA45642A (uk) | Спосіб метафілактики оксалатного уролітіазу | |
| Arie et al. | Crystal-associated rheumatic disease: Current management considerations | |
| RU2823132C1 (ru) | Способ профилактики послеоперационных осложнений у стоматологических больных с постковидным синдромом | |
| RU2362564C1 (ru) | Способ медикаментозной коррекции 2 стадии желчекаменной болезни у пациентов с описторхозом | |
| RU2702607C1 (ru) | Способ лечения туберкулеза мочевого пузыря | |
| JP2006045200A (ja) | 間質性膀胱炎の治療薬 | |
| Abiteboul et al. | Septic arthritis of the knee due to Neisseria mucosa | |
| Thamarai Selvi et al. | Comparative Evaluation Of Post-Operative Pain Following Extraction Of Impacted Third Molar With Different Groups Of Analgesics-A Clinical Study | |
| WO2019125577A1 (en) | Method of treatment of diabetic foot ulcers | |
| US20080194471A1 (en) | Compositions and Methods for Treating Wounds | |
| Boulton-Jones | Acute and chronic renal failure | |
| GREENBERG et al. | Methylene Blue in the Treatment of Urinary Tuberculosis | |
| Vetvik et al. | Effect of misoprostol and antacids on gastric and duodenal mucosal enzyme activities in duodenal ulcer patients |